Comparison of the Direct Anterior Approach (DAA) and the Direct Lateral Approach (DLA) in Patients Treated With Partial Hip Replacement for Femoral Neck Fracture Based on Postoperative Functional Status

March 24, 2026 updated by: Meir Medical Center

Impact of Surgical Approach on Post-Fracture Function: A Prospective Hemiarthroplasty Study

The goal of this clinical trial is to learn whether the surgical approach used for hemiarthroplasty can improve clinical and functional outcomes in adults with displaced femoral neck fractures.

The main questions it aims to answer are:

  • Does the direct anterior approach (DAA) result in superior postoperative functional recovery compared with the direct lateral approach (DLA)?
  • Are mortality, complications, hospital utilization, and readmission rates different between the two surgical approaches? Researchers will compare hemiarthroplasty performed using the direct anterior approach to hemiarthroplasty performed using the direct lateral approach to determine whether surgical approach influences postoperative function, complications, and survival.

Participants will:

  • Undergo hemiarthroplasty for displaced femoral neck fracture using a randomly assigned surgical approach (DAA or DLA)
  • Complete a baseline functional assessment using the Activities of Daily Living (ADL) questionnaire before surgery
  • Have perioperative data collected during hospitalization, including laboratory values, operative details, blood loss, transfusions, analgesic use, complications, length of stay, and in-hospital mortality
  • Attend follow-up clinic visits at 6 weeks and 3 months after surgery
  • Complete postoperative functional assessment using the Harris Hip Score at both follow-up visits
  • Have demographic data, complications, readmissions, and mortality monitored through review of electronic medical records

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of adult patients undergoing hemiarthroplasty for displaced femoral neck fracture at Meir Medical Center during the study period.

Description

Inclusion Criteria:

Adults aged 18 years or older Patients undergoing hemiarthroplasty (partial hip replacement) during the study period at Meir Medical Center Ability to provide informed consent for participation in the study

Exclusion Criteria:

Revision surgery performed during the index hospitalization Inability to complete postoperative follow-up Inability to provide informed consent (e.g., dementia or presence of a legal guardian) Pre-injury mobility status of bedbound or wheelchair-bound Polytrauma patients Prior fixation or arthroplasty of the contralateral hip within the previous year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Harris Hip Score (HHS) - Postoperative Functional Outcome at 6 Weeks and 3 Months Following Hemiarthroplasty
Time Frame: 6 weeks and 3 months post-surgery
Functional outcome will be assessed using the Harris Hip Score (HHS), a validated 100-point scale evaluating pain, function, deformity, and range of motion, collected at 6 weeks and 3 months postoperatively.
6 weeks and 3 months post-surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Related Complications Following Hemiarthroplasty
Time Frame: During hospitalization and up to 3 months post-surgery
Number of participants with one or more complications- Including intraoperative blood loss, blood transfusions, implant dislocation, implant failure, surgical site infection, and other adverse events.
During hospitalization and up to 3 months post-surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

May 1, 2028

Study Completion (Estimated)

May 1, 2028

Study Registration Dates

First Submitted

March 16, 2026

First Submitted That Met QC Criteria

March 24, 2026

First Posted (Actual)

March 30, 2026

Study Record Updates

Last Update Posted (Actual)

March 30, 2026

Last Update Submitted That Met QC Criteria

March 24, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 0046-26-MMC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.